Methylphenidate Shortage Update: Concerta and Ritalin LA Supply Restored, Rubifen LA Expected by June 2026
Australia's methylphenidate shortage shows improvement as Concerta and Ritalin LA supplies normalize, while Rubifen LA shortages persist until mid-2026.
Intelligence Snapshot
Executive Summary
Shortages of most methylphenidate modified-release products, including Concerta and Ritalin LA, have been resolved
Key Insights
- Rubifen LA capsules remain unavailable across all strengths until the end of June 2026
-
Three major pharmaceutical companies - Janssen-Cilag, Novartis, and AFT Pharmaceuticals -…
Three major pharmaceutical companies - Janssen-Cilag, Novartis, and AFT Pharmaceuticals - reported supply disruptions during 2024-2025
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Executive Scorecard
Heuristic scores · directional, not investment adviceContents6 sections
Key Takeaways
- Shortages of most methylphenidate modified-release products, including Concerta and Ritalin LA, have been resolved
- Rubifen LA capsules remain unavailable across all strengths until the end of June 2026
- Three major pharmaceutical companies - Janssen-Cilag, Novartis, and AFT Pharmaceuticals - reported supply disruptions during 2024-2025
Australia’s Therapeutic Goods Administration (TGA) has announced significant progress in resolving methylphenidate hydrochloride shortages that have affected ADHD patients throughout 2024 and early 2025.
Supply Status Improves for Key ADHD Medications
The shortage crisis that impacted multiple methylphenidate formulations has largely stabilized, with Janssen-Cilag’s Concerta modified-release tablets and Novartis’s Ritalin LA modified-release capsules now returning to normal supply levels. These medications are critical treatments for attention deficit hyperactivity disorder (ADHD) and narcolepsy.
However, patients relying on AFT Pharmaceuticals’ Rubifen LA capsules face continued challenges, as all strengths of this formulation remain unavailable until at least the end of June 2026.
IntelligenceRegulatory Impact
TGA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in Asia-Pacific. Regulatory relevance reads medium for pharmaceutical intelligence. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.
Industry-Wide Supply Chain Disruptions
The shortages stemmed from supply chain issues reported by three major pharmaceutical sponsors: Janssen-Cilag, Novartis, and AFT Pharmaceuticals. These companies formally notified the TGA about their inability to maintain adequate stock levels of their respective methylphenidate products during the 2024-2025 period.
Methylphenidate hydrochloride is a controlled substance and essential medication for managing ADHD symptoms, making supply continuity crucial for patient care. The drug works by affecting neurotransmitters in the brain to improve focus, attention, and impulse control.
IntelligenceCompetitive Intelligence
Competitive pressure is low on capacity and tech-transfer positioning. Benchmark which CDMOs, equipment vendors, and sponsors adopt continuous and isolator platforms first. Supplier hub and pipeline links below connect to named partners.
Market Impact and Patient Considerations
The resolution of most methylphenidate shortages provides relief for healthcare providers and patients who have faced treatment disruptions. However, the extended timeline for Rubifen LA availability may require ongoing medication management adjustments for affected patients.
Healthcare professionals have been working with patients to identify suitable alternatives during shortage periods, including switching between different methylphenidate formulations or adjusting dosing schedules based on available products.
Frequently Asked Questions
What does this mean for patients currently taking these medications?
Patients taking Concerta or Ritalin LA should now have improved access to their medications as shortages have resolved. Those on Rubifen LA will need to work with their healthcare provider to find alternatives until June 2026.
When will Rubifen LA be available again?
AFT Pharmaceuticals expects Rubifen LA capsules in all strengths to become available by the end of June 2026, according to the TGA update.
Are there alternative treatments available during shortages?
Yes, healthcare providers can prescribe other methylphenidate formulations or alternative ADHD medications. Patients should consult their doctor about switching medications rather than going without treatment.
Related coverage
Ask AI About This Topic
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
- Evidence strength
- 71/100
- Last verified
- Jun 16, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Moderate source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
